Alembic Pharmaceuticals Limited — Credit Ratings, 12-06-2025: Credit Rating

CARE Ratings has reaffirmed Alembic Pharmaceuticals’ commercial paper rating at CARE A1+ and increased the limit to ₹1,100 crore from ₹750 crore. This reflects stable operational and financial performance in FY25, supporting strong short-term creditworthiness. The rating action highlights sustained liquidity and effective debt management, which should help the company maintain competitive borrowing costs and strengthen investor confidence. The higher commercial paper limit also offers greater flexibility for managing working capital and short-term funding.